161 related articles for article (PubMed ID: 15907786)
1. Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors.
Fricker M; Lograsso P; Ellis S; Wilkie N; Hunt P; Pollack SJ
Arch Biochem Biophys; 2005 Jun; 438(2):195-205. PubMed ID: 15907786
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of JNK3: a kinase implicated in neuronal apoptosis.
Xie X; Gu Y; Fox T; Coll JT; Fleming MA; Markland W; Caron PR; Wilson KP; Su MS
Structure; 1998 Aug; 6(8):983-91. PubMed ID: 9739089
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38.
Kamenecka T; Habel J; Duckett D; Chen W; Ling YY; Frackowiak B; Jiang R; Shin Y; Song X; LoGrasso P
J Biol Chem; 2009 May; 284(19):12853-61. PubMed ID: 19261605
[TBL] [Abstract][Full Text] [Related]
4. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.
Fox T; Coll JT; Xie X; Ford PJ; Germann UA; Porter MD; Pazhanisamy S; Fleming MA; Galullo V; Su MS; Wilson KP
Protein Sci; 1998 Nov; 7(11):2249-55. PubMed ID: 9827991
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis for p38 protein kinase inhibitor specificity.
Lisnock J; Tebben A; Frantz B; O'Neill EA; Croft G; O'Keefe SJ; Li B; Hacker C; de Laszlo S; Smith A; Libby B; Liverton N; Hermes J; LoGrasso P
Biochemistry; 1998 Nov; 37(47):16573-81. PubMed ID: 9843424
[TBL] [Abstract][Full Text] [Related]
6. Oxidation-triggered c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase pathways for apoptosis in human leukaemic cells stimulated by epigallocatechin-3-gallate (EGCG): a distinct pathway from those of chemically induced and receptor-mediated apoptosis.
Saeki K; Kobayashi N; Inazawa Y; Zhang H; Nishitoh H; Ichijo H; Saeki K; Isemura M; Yuo A
Biochem J; 2002 Dec; 368(Pt 3):705-20. PubMed ID: 12206715
[TBL] [Abstract][Full Text] [Related]
7. Galloyl benzamide-based compounds modulating tumour necrosis factor α-stimulated c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signalling pathways.
Leo V; Stefanachi A; Nacci C; Leonetti F; de Candia M; Carotti A; Altomare CD; Montagnani M; Cellamare S
J Pharm Pharmacol; 2015 Oct; 67(10):1380-92. PubMed ID: 26078032
[TBL] [Abstract][Full Text] [Related]
8. Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1.
Ember B; Kamenecka T; LoGrasso P
Biochemistry; 2008 Mar; 47(10):3076-84. PubMed ID: 18269248
[TBL] [Abstract][Full Text] [Related]
9. Stress-activated protein kinase/c-Jun N-terminal kinase (JNK) plays a part in endothelin-1-induced vascular endothelial growth factor synthesis in osteoblasts.
Wang X; Tokuda H; Hirade K; Kozawa O
J Cell Biochem; 2002; 87(4):417-23. PubMed ID: 12397601
[TBL] [Abstract][Full Text] [Related]
10. Differences in activation of ERK1/2 and p38 kinase in Jnk3 null mice following KA treatment.
de Lemos L; Junyent F; Verdaguer E; Folch J; Romero R; Pallàs M; Ferrer I; Auladell C; Camins A
J Neurochem; 2010 Sep; 114(5):1315-22. PubMed ID: 20534003
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket.
Gum RJ; McLaughlin MM; Kumar S; Wang Z; Bower MJ; Lee JC; Adams JL; Livi GP; Goldsmith EJ; Young PR
J Biol Chem; 1998 Jun; 273(25):15605-10. PubMed ID: 9624152
[TBL] [Abstract][Full Text] [Related]
12. JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T-cells: differential requirements for caspase activation.
MacFarlane M; Cohen GM; Dickens M
Biochem J; 2000 May; 348 Pt 1(Pt 1):93-101. PubMed ID: 10794718
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of inhibitor selectivity in MAP kinases.
Wang Z; Canagarajah BJ; Boehm JC; Kassisà S; Cobb MH; Young PR; Abdel-Meguid S; Adams JL; Goldsmith EJ
Structure; 1998 Sep; 6(9):1117-28. PubMed ID: 9753691
[TBL] [Abstract][Full Text] [Related]
14. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
15. IKappaB-kinase/nuclear factor-kappaB signaling prevents thermal injury-induced gut damage by inhibiting c-Jun NH2-terminal kinase activation.
Chen LW; Chen PH; Chang WJ; Wang JS; Karin M; Hsu CM
Crit Care Med; 2007 May; 35(5):1332-40. PubMed ID: 17414734
[TBL] [Abstract][Full Text] [Related]
16. Noradrenaline reduces the ATP-stimulated phosphorylation of p38 MAP kinase via beta-adrenergic receptors-cAMP-protein kinase A-dependent mechanism in cultured rat spinal microglia.
Morioka N; Tanabe H; Inoue A; Dohi T; Nakata Y
Neurochem Int; 2009 Sep; 55(4):226-34. PubMed ID: 19524113
[TBL] [Abstract][Full Text] [Related]
17. Structural Mechanism of the Arrestin-3/JNK3 Interaction.
Park JY; Qu CX; Li RR; Yang F; Yu X; Tian ZM; Shen YM; Cai BY; Yun Y; Sun JP; Chung KY
Structure; 2019 Jul; 27(7):1162-1170.e3. PubMed ID: 31080119
[TBL] [Abstract][Full Text] [Related]
18. A novel retro-inverso peptide is a preferential JNK substrate-competitive inhibitor.
Ngoei KR; Catimel B; Milech N; Watt PM; Bogoyevitch MA
Int J Biochem Cell Biol; 2013 Aug; 45(8):1939-50. PubMed ID: 23792175
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis induced by domoic acid in mouse cerebellar granule neurons involves activation of p38 and JNK MAP kinases.
Giordano G; Klintworth HM; Kavanagh TJ; Costa LG
Neurochem Int; 2008 May; 52(6):1100-5. PubMed ID: 18164102
[TBL] [Abstract][Full Text] [Related]
20. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
